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Abstract 
Aim: We surveyed prognostic biomarkers for resectable non-small cell lung cancer (NSCLC). 
Patients and Methods: We obtained preoperative serum from 109 patients, and measured the levels 
of hepatocyte growth factor (HGF), interleukin-6 (IL-6), and nicotinamide N-methytransferase 
(NNMT) in the sera. Results: The median HGF and IL-6 contents were 860 pg/ml and 2.7 pg/ml, 
respectively. Analysis of survival curves indicated that an HGF or IL-6 level higher than the 
median was associated with poor overall survival (HGF, p=0.019; IL-6, p=0.002). In addition, we 
analyzed stage III lung cancer alone. Higher HGF and IL-6 levels were associated with poor overall 
survival (HGF, p=0.016; IL-6, p=0.013). Disease-free survival was not statistically significantly 
affected by these cytokine contents. The tumor status (pT factor) and nodal status (pN factor) were 
not associated with the survival of stage III patients. Conclusion: The levels of HGF and IL-6 in 
serum could be useful prognostic indicators of the survival of patients with stage III NSCLC 
undergoing surgery and chemotherapy.  
  
Introduction 
Lung cancer is a fatal malignant tumor that develops at high frequency in most countries at present. 
There are no tumor markers that are sufficiently useful for detecting lung cancer at a stage where 
the patients can be cured completely. We previously examined whether or not nicotinamide N-
methytransferase (NNMT) is a potential biomarker of non-small cell lung cancer (NSCLC) (1, 2). 
The serum levels of NNMT were significantly higher in patients with lung cancer than in healthy 
donors and in patients with non-neoplastic disease.  
In the present study, we analyzed prognostic factors in 109 cancer patients. Surgical resection of 
the tumor is the principle form of treatment for patients with stage I or stage II lung cancer. 
However, treatment of patients with stage III disease is not as simple. Some patients with stage III 
disease undergo surgery for tumor resection. Another treatment option is preoperative 
chemoradiotherapy and, if a response is seen, application of follow-up resectioning of any 
remaining tumor. The remaining patients are not surgical candidates. Therefore, predictors of the 
prognosis in stage III NSCLC would be useful for selection of the most appropriate treatment (3).  
Hepatocyte growth factor (HGF) was originally found as a blood-derived factor released during 
regeneration of the liver (4, 5). At present, it is recognized that this factor is involved in the 
development of various organs during embryogenesis and tissue regeneration. Although HGF is 
produced mainly by mesenchymal cells, it acts on epidermal- and endothelial-derived cells (6, 7). 
It is also involved in cancer growth and metastasis by enhancing the motility of cancer cells and 
by stimulating angiogenesis (8, 9). The hepatocyte growth factor receptor (c-MET), proto-
oncogene product, is expressed on most epidermal cells and a wide variety of cancer cells (7). 
Clinical studies have shown an association between the concentration of HGF in serum or cancer 
tissue and the progression of the disease in various cancer types, including breast (10, 11), gastric 
(12), bladder (13), colorectal (14), and small cell lung (15) cancer, myeloma (16, 17), and synovial 
sarcoma (18). For NSCLC, the intratumoral HGF level was reported to be a prognostic indicator 
(19 - 21), but the significance of the serum HGF level was not reported until fairly recently (22, 
23). HGF is mainly produced by stromal fibroblasts (24). We previously showed that the HGF 
gene in cancer cells is transcriptionally activated by leukemia inhibitory factor (LIF) through the 
signal transducers and activators of transcription 3 (STAT3) (25). Furthermore, the expression of 
HGF in human lung fibroblasts and MRC-5 cells, derived from lung fibroblasts is correlated with 
that of IL-6. Expression of the HGF gene in MRC-5 cells was suppressed by treatment with 
curcumin, an inhibitor of STAT3 (unpublished results). Therefore, cytokines, such as LIF and IL-
6, that activate STAT3 might stimulate stromal cells to produce HGF.  
The inflammatory cytokine IL-6 exhibits multiple functions and stimulates the progression of 
various kinds of cancers (17, 26, 27). Constitutive activation of the STAT3 pathway in alveolar 
epithelial cells induces inflammation and adenocarcinomas in mouse lungs (28). In human lung 
adenocarcinoma, mutant epidermal growth factor receptor (EGFR) activates the STAT3 pathway 
through IL-6 up-regulation (29). It has been reported that increased serum IL-6 levels were 
associated with poor survival in patients with NSCLC (30, 31).  
In this study, we analyzed the relationship between the levels of HGF, IL-6 and NNMT in sera, 
and the survival of patients with NSCLC.  
 
Patients and Methods 
Serum samples. This study and the use of blood samples collected after obtaining informed consent, 
were approved by the Ethical Committee of the Saitama Cancer Center (1). As preoperative blood 
samples, serum was collected from 109 patients undergoing radical pulmonary resection at the 
Department of Thoracic Surgery of Saitama Cancer Center Hospital during the period November 
2006 to November 2007. The blood was maintained at room temperature for 20 min before 
centrifugation. The serum was separated, and then frozen at −70°C.  
The 109 lung cancer patients included 79 with adenocarcinoma, 26 with squamous cell carcinoma 
(SCC), and 4 with other non-small cell lung cancer (Table I). For the examined tumors, the 
pathological stage was determined based on the standard criteria, UICC 7th edition (32).  
Enzyme linked immunosorbent assay (ELISA) of cytokines and NNMT. ELISA assays for HGF and 
IL-6 were performed using a Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA), 
according to the manufacturer's instructions. The levels of NNMT were measured by a method 
developed by Tomida et al. 2009 (1). The limit of detection for this method is 30 pg NNMT. The 
levels of carcinoembryonic antigen (CEA) were measured by routine examination at our hospital.  
Statistical analysis. The relationships between the clinical outcome, and the HGF and IL-6 
contents were analyzed by means of the Mann Whitney or Kruskal Wallis test. The correlation 
was examined by means of Spearman's rank correlation test. Regarding the total survival period 
and disease-free period, we prepared a Kaplan Meier survival curve (33). Univariate analysis of 
prognostic factors was performed by means of the log-rank test. Multivariate analysis was 
performed using the Cox proportional-hazards model (34). Statistical calculations were performed 
using the SPSS software (ver.17.0) (IBM, Chicago, IL, USA). When the two-sided p-value was 
lower than 0.05, statistical significance was considered.  
 Results 
Table I shows the clinical profiles of the 109 patients, and the HGF and IL-6 levels in each group. 
The levels of HGF detected in serum samples of various patients were in the range of 215-2,000 
pg/ml. The median HGF level in the 109 patients was 860 pg/ml, with the average being 875 pg/ml. 
The HGF levels were not significantly different between the groups.  
The IL-6 levels detected in the serum samples from the 109 patients were in the range of 0-62 
pg/ml. The median IL-6 level was 2.7 pg/ml, with the average being 5.0 pg/ml. The IL-6 
concentrations were significantly higher in older patients and in patients with SCC.  
The relationship between the HGF and IL-6 levels in the sera from the patients was examined. As 
shown in Figure 1, the HGF levels were correlated with the IL-6 concentrations (Spearman's 
correlation coefficient by rank test: r=0.435; p<0.0001).  
For the analysis of overall survival of the 109 patients, the median HGF value (860 pg/ml) was 
used as the cut-off. As shown in Figure 2a, patients with low HGF levels had a significantly better 
overall survival than ones with elevated HGF levels (p=0.019). For the patients who died during 
the follow-up observation period, the median HGF level was 1,025 pg/ml. On the other hand, the 
median HGF level in the surviving patients was 738 pg/ml, with there being a significant difference 
(p=0.036).  
The IL-6 level was also associated with overall survival when the median IL-6 level (2.7 pg/ml) 
was used as the cut-off value (p=0.002) (Figure 2b). The median IL-6 level, 4.0 pg/ml, in the 
patients who died was higher than that of 2.3 pg/ml in the survivors (p=0.027).  
Tumor marker CEA was reported to be a prognostic factor for patients with surgically resected 
NSCLC (3). We analyzed CEA and NNMT, which we reported as candidate tumor markers for 
NSCLC (1). However, the CEA and NNMT levels were not associated with the overall survival 
rate (Figure 2c and d).  
When examining the overall survival rate of patients at individual disease stages, a difference was 
confirmed in the survival rate between patients with disease at stages I-II and III (p=0.0005). The 
analyzed patients included 50 patients at stage I, 17 at stage II, and 38 at stage III. Since the number 
of patients with disease at stage II was small, and they principally underwent the same surgery as 
in patients at stage I, the patients at stages I and II were analyzed together (Table I). The T status 
(pT factor) was also a strong prognostic factor.  
In this study, the prognosis of patients with adenocarcinoma was better than that of patients with 
other types of NSCLC (p=0.007). The prognosis of female patients was also better than that of 
male ones (p=0.023). On univariate analysis, it was found that gender, stage, histological type, 
HGF level, IL-6 level, pT, and pN contributed to the overall survival rate (Table II).  
On multivariate analysis of the overall survival rate, IL-6 (p=0.034, hazard ratio HR=3.46), pN 
factor (p=0.004, HR=3.71), and pT factor (p=0.001, HR=4.41) were statistically significant (Table 
II).  
On analysis of the disease-free survival period, histological type, stage, pN factor and pT factor 
were found to be significant on univariate analysis, and histological type (p=0.02, HR=2.40) and 
pN factor (p=0.036, HR 2.41) to be significant on multivariate analysis (Table II).  
Next, we analyzed the patients with stage III disease separately (Table III). Elevated HGF and IL-
6 levels were associated with poor overall survival (Figure 3b and d). Disease-free survival was 
also affected by these cytokines, but not statistically significantly (Figure 3a and c). The pT and 
pN factors were not related to overall or disease-free survival of patients with stage III disease.  
The results of multivariate analysis of overall survival of stage III patients are shown in Table III. 
Because there is a correlation between the IL-6 and HGF levels, each HR is significant only when 
the other factor is omitted from the analysis. A poorer prognosis was associated with higher HGF 
levels (p=0.038, HR=3.97) and higher IL-6 levels (p=0.045 HR=4.76). The prognosis of patients 
with NSCLC other than adenocarcinoma was poorer than that of those with adenocarcinoma, but 
not statistically significantly when IL-6 was included in the analysis, since the histological types 
affected IL-6 level (Table I).  
On the other hand, the HGF and IL-6 levels were not associated with overall or disease-free 
survival of patients with stage I-II disease (Figure 3e and f).  
Furthermore, we analyzed the overall survival of 109 patients based on combinations of the HGF 
and IL-6 levels (Figure 4). In patients with low HGF and low IL-6 levels, prognosis was favorable 
and the survival rate was 93%. On the other hand, the survival rate in patients with high levels of 
both cytokines, who had the poorest prognosis, was 56%. The survival rates in patients with high 
HGF and low IL-6 levels, and those with low HGF and high IL-6 levels, were 86% and 78%, 
respectively. Therefore, it would be effective in regard to prediction of the survival rate to use a 
combination of two biomarkers (p=0.0011).  
 
Discussion 
The results found in this study suggest that the HGF and IL-6 levels in blood are useful as 
predictors of the aggressive characteristics of stage III NSCLC. Since it is known that HGF is a 
stimulating factor for infiltration, and that it induces cell division and angiogenesis, a high HGF 
level in blood may be a marker suggesting latent metastasis. It is also suggested that cytokines, 
such as IL-6, released from a tumor and inflammatory cells stimulate fibroblasts in the lungs to 
produce HGF (24, 25). In addition, IL-6 directly stimulates the progression of lung tumor (29). It 
was reported that the IL-6 level would increase with increasing NSCLC stage, suggesting a 
correlation between high efficacy of chemotherapy and low IL-6 level in blood (34, 35). If tumor 
cells move from the primary tumor site and then induce local release of IL-6 and HGF, this will 
contribute to aggravation of the disease. Our study results showed a correlation between HGF and 
IL-6 levels, suggesting that IL-6 levels would reflect the HGF levels to a certain extent.  
Disease-free survival was affected by these cytokines, but the correlation between relapse and 
these cytokines was not statistically significant. Chemotherapy may affect overall survival. 
Recently, the serum HGF levels in patients with advanced NSCLC were analyzed (22, 23). An 
association between HGF and gefitinib resistance was found in accordance with previous studies 
showing that the HGF/MET pathway played a role in the development of gefitinib resistance in 
NSCLC with an EGFR gene mutation (37, 38). It has also been reported that IL-6 is a biomarker 
of resistance to multitargeted receptor tyrosine kinase inhibitors in prostate cancer (39). In our 
study, patients with resectable stage III cancer were subjected to adjuvant chemotherapy using 
paclitaxel and carboplatin, but not gefitinib. Our results suggest that HGF and IL-6 generally 
stimulate resistance to chemotherapy. It has been reported that IL-6 reduces the sensitivity of 
cancer cells to chemotherapeutic agents, such as paclitaxel and cisplatin, by activating the 
PI3K/AKT and STAT3 pathways in cells (40); HGF has similar actions (41).  
All these studies show that HGF and IL-6 are good molecular targets for cancer therapy (42 - 
44). Our findings suggest that patients with stage III NSCLC who have low levels of HGF and 
IL-6 should be considered to be surgical candidates. 
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Figure 1. 
 
 
The serum levels of hepatocyte growth factor (HGF) in patients with lung cancer were correlated 
with those of interleukin-6 (IL-6). The correlation was examined by means of Spearman's rank-
correlation test.  
  
Figure 2. 
 
Overall survival curves for 109 lung cancer patients, according to the hepatocyte growth factor 
(HGF) (a), interleukin-6 (IL-6) (b), nicotinamide N–methytransferase (NNMT) (c), and 
carcinoembryonic antigen (CEA) (d) levels. The cut-off values are shown in Table II. 
  
Figure 3. 
 
Disease-free and overall survival curves for patienrs with stage III (a-d) and stage I-II (e-f) 
disease, according to the hepatocyte growth factor (HGF) (a, b, e) and interleukin-6 (IL-6) (c, d, 
f) levels. 
  
Figure 4. 
 
Overall survival curves for 109 lung cancer patients, according to the combination of hepatocyte 
growth factor (HGF) and interleukin-6 (IL-6) levels.   
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